Adoptive immunotherapy after hematopoietic stem cell transplantation

Richard K. Burt*, Charles Link, Ann Traynor

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Adoptive immunotherapy may be performed with either autologous or allogeneic lymphocytes. Autologous cellular immunotherapy is hindered by the inability to break anergy or self-tolerance. Advances in this area have focused on the use of tumor-specific lymphocytes activated by antigen-pulsed or transgene modified dendritic cells. Allogeneic cellular immunotherapy is effective even with the use of non-specific and unactivated donor lymphocytes. Allogeneic cellular therapy is, however, complicated by graft-versus-host disease (GVHD). Advances in allogeneic immunotherapy will require better control of GVHD.

Original languageEnglish (US)
Pages (from-to)525-532
Number of pages8
JournalCurrent opinion in oncology
Issue number6
StatePublished - 1998

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adoptive immunotherapy after hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this